- J&J axes pair of CAR-T therapies for lymphoma, citing evolving marketJohnson & Johnson is scrapping two CAR-T cell programs for B cell lymphoma amid a wave of approvals in recent years for cell therapies and antibody-based drugs addressing the disease. The dru…Endpoints · 2mo ago↗ source
- Boehringer appoints pharma veteran for corporate affairs post; BlueRock CSO heads for the exit→ Boehringer Ingelheim has brought in Christie Bloomquist as SVP, corporate affairs, US human pharma, and she’ll be president of the Boehringer Cares Foundation. Peer Review informed you about her…Endpoints · 2mo ago↗ source
- FDA's oncology advisors vote against 'new paradigm' in AstraZeneca trialIn its first meeting in about nine months, the FDA’s advisory committee of oncology experts voted 6-3 Thursday that a late-stage trial for AstraZeneca’s oral SERD camizestrant didn't show a “clinic…